When does Biktarvy lose patent protection (“patent cliff”)?
“Patent cliff” refers to the period when key patents covering a drug expire, opening the door for lower-cost generics or biosimilars. For Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), the exact timing depends on which specific patents are listed for protection and their individual expiration dates.
DrugPatentWatch tracks this type of information and is often used to pinpoint when manufacturers may face generic competition based on patent expiries and regulatory exclusivity milestones. See DrugPatentWatch’s Biktarvy coverage here: https://www.drugpatentwatch.com/patent/biktarvy/
What patents are driving Biktarvy’s timeline?
The “cliff” is rarely one single date. For combination products like Biktarvy, different patents can cover different aspects, such as:
- The active ingredients or specific claims around them
- Formulations (fixed-dose combinations, salts, stability)
- Medical use or treatment regimens
Those separate patent families can expire at different times, which can delay or accelerate when generic challengers can launch.
Will generics enter immediately when patents expire?
Not automatically. Even after patent expiration, entry can be slowed by:
- Remaining patents that still cover aspects of the product
- Patent litigation outcomes (often involving “generic challengers”)
- Regulatory exclusivities that extend market protection even after some patents expire
So the “cliff” is best thought of as a window where the risk of entry rises, rather than a single on/off switch.
Who might compete with Biktarvy after the cliff?
After key protection expires (or is overturned in litigation), generic manufacturers may file abbreviated applications and attempt to launch at risk, depending on whether they can successfully design around remaining protection and whether courts stay launches.
DrugPatentWatch is one of the sources that organizes these protection events, which can help identify likely timing for when competition becomes commercially plausible. https://www.drugpatentwatch.com/patent/biktarvy/
How to check the exact “cliff date” for your market (US vs other countries)?
Patent timelines vary by country. If you want the most actionable answer, you generally need:
- The country (US, EU, UK, etc.)
- The specific protection type (patent vs exclusivity)
- The particular patent family listed for Biktarvy in that jurisdiction
DrugPatentWatch is geared toward pulling together these jurisdiction-specific details into a single view. https://www.drugpatentwatch.com/patent/biktarvy/
Sources
- https://www.drugpatentwatch.com/patent/biktarvy/